Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The G protein-gated inwardly rectifying potassium channel (IKACh) is a cardiac potassium channel that mediates the acetylcholine-sensitive K+ current in atrial and nodal myocytes. It is a heterotetrameric structure typically composed of Kir3.1 (GIRK1) and Kir3.4 (GIRK4) subunits, and is activated by direct binding of Gβγ subunits from muscarinic M2 receptor–coupled G-proteins in response to parasympathetic stimulation. IKACh activation increases potassium permeability, causing membrane hyperpolarization and shortening of the cardiac action potential, especially in the atria, thereby slowing the heart rate and facilitating vagal control of cardiac rhythm. IKACh is implicated in multiple cardiac pathologies, especially arrhythmias such as atrial fibrillation, and is a validated drug target for modulating cardiac electrical behavior.
Blockage of IKACh: increases heart rate, used in bradycardia or to terminate vagal-induced arrhythmias; Activation of IKACh: slows heart rate via hyperpolarization and shortening of action potential duration
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-gated inwardly rectifying potassium channel (IKACh) (IKACh).